evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

100 questions · 100 findings · 41 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 31 · 31%GRADE not reported 4 · 4%Very low 34 · 34%Low 19 · 19%Moderate 10 · 10%High 2 · 2%

Celecoxib vs placebo

Number of participants experiencing any serious adverse events · patients with osteoarthritis

It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Laser ablation vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether laser ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).

1 finding from 1 review

Percutaneous ethanol injection vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).

1 finding from 1 review

Intervention not reported

The number of patients with serious adverse events · patients with relapsing‐remitting multiple sclerosis

The intervention showed no clear difference in the number of patients with serious adverse events (low certainty).

1 finding from 1 review

Diacerein vs placebo

Total number of serious adverse events not measured · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Paracetamol vs placebo

Serious adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Supervised dosing with a long‐acting medication vs unsupervised consumption

Adverse serious events (any) (number of participants) · patients with opioid dependence

It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with any serious adverse events · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review